gefitinib has been researched along with spironolactone in 5 studies
Studies (gefitinib) | Trials (gefitinib) | Recent Studies (post-2010) (gefitinib) | Studies (spironolactone) | Trials (spironolactone) | Recent Studies (post-2010) (spironolactone) |
---|---|---|---|---|---|
5,231 | 566 | 2,919 | 7,222 | 960 | 1,923 |
Protein | Taxonomy | gefitinib (IC50) | spironolactone (IC50) |
---|---|---|---|
Chain A, Mineralocorticoid receptor | Homo sapiens (human) | 0.049 | |
Chain A, Mineralocorticoid receptor | Homo sapiens (human) | 0.049 | |
Estrogen receptor | Homo sapiens (human) | 5.702 | |
Glucocorticoid receptor | Homo sapiens (human) | 4.0745 | |
Progesterone receptor | Homo sapiens (human) | 1.675 | |
Glycine receptor subunit alpha-1 | Rattus norvegicus (Norway rat) | 1.9025 | |
Mineralocorticoid receptor | Homo sapiens (human) | 0.0315 | |
Androgen receptor | Homo sapiens (human) | 0.3585 | |
Androgen receptor | Rattus norvegicus (Norway rat) | 0.406 | |
Glycine receptor subunit beta | Rattus norvegicus (Norway rat) | 1.9025 | |
Glycine receptor subunit alpha-2 | Rattus norvegicus (Norway rat) | 1.9025 | |
Glycine receptor subunit alpha-3 | Rattus norvegicus (Norway rat) | 1.9025 | |
Sodium-dependent serotonin transporter | Rattus norvegicus (Norway rat) | 6.92 | |
Cytochrome P450 2C19 | Homo sapiens (human) | 3 |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 2 (40.00) | 29.6817 |
2010's | 3 (60.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Andricopulo, AD; Moda, TL; Montanari, CA | 1 |
Artursson, P; Bergström, CA; Hoogstraate, J; Matsson, P; Norinder, U; Pedersen, JM | 1 |
Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
Ekins, S; Williams, AJ; Xu, JJ | 1 |
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
1 review(s) available for gefitinib and spironolactone
Article | Year |
---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
4 other study(ies) available for gefitinib and spironolactone
Article | Year |
---|---|
Hologram QSAR model for the prediction of human oral bioavailability.
Topics: Administration, Oral; Biological Availability; Holography; Humans; Models, Biological; Models, Molecular; Molecular Structure; Pharmaceutical Preparations; Pharmacokinetics; Quantitative Structure-Activity Relationship | 2007 |
Prediction and identification of drug interactions with the human ATP-binding cassette transporter multidrug-resistance associated protein 2 (MRP2; ABCC2).
Topics: Administration, Oral; Animals; Antineoplastic Agents; Antipsychotic Agents; Antiviral Agents; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Biological Transport; Cell Line; Computer Simulation; Cytochrome P-450 Enzyme System; Drug-Related Side Effects and Adverse Reactions; Estradiol; Humans; Insecta; Liver; Models, Molecular; Multidrug Resistance-Associated Protein 2; Multidrug Resistance-Associated Proteins; Neoplasm Proteins; Pharmaceutical Preparations; Pharmacology; Structure-Activity Relationship | 2008 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
A predictive ligand-based Bayesian model for human drug-induced liver injury.
Topics: Bayes Theorem; Chemical and Drug Induced Liver Injury; Humans; Ligands | 2010 |